Opaque Ontology: Neuroimaging Classification of ICD-10 Diagnostic Groups in the UK Biobank.
Opaque Ontology: Neuroimaging Classification of ICD-10 Diagnostic Groups in the UK Biobank.
复制标题
不透明本体论:英国生物银行 ICD-10 诊断组的神经影像分类。
DOI:
10.1101/2024.04.15.589555
复制
发表时间:
2024
期刊:
影响因子:
--
通讯作者:
Bijsterbosch,Janine
中科院分区:
文献类型:
--
作者:
Easley,Ty;Luo,Xiaoke;Hannon,Kayla;Lenzini,Petra;Bijsterbosch,Janine
BackgroundThe use of machine learning to classify diagnostic cases versus controls defined based on diagnostic ontologies such as the International Classification of Diseases, Tenth Revision (ICD-10) from neuroimaging features is now commonplace across a wide range of diagnostic fields. However, transdiagnostic comparisons of such classifications are lacking. Such transdiagnostic comparisons are important to establish the specificity of classification models, set benchmarks, and assess the value of diagnostic ontologies.ResultsWe investigated case-control classification accuracy in 17 different ICD-10 diagnostic groups from Chapter V (mental and behavioral disorders) and Chapter VI (diseases of the nervous system) using data from the UK Biobank. Classification models were trained using either neuroimaging (structural or functional brain magnetic resonance imaging feature sets) or sociodemographic features. Random forest classification models were adopted using rigorous shuffle-splits to estimate stability as well as accuracy of case-control classifications. Diagnostic classification accuracies were benchmarked against age classification (oldest vs. youngest) from the same feature sets and against additional classifier types (k-nearest neighbors and linear support vector machine). In contrast to age classification accuracy, which was high for all feature sets, few ICD-10 diagnostic groups were classified significantly above chance (namely, demyelinating diseases based on structural neuroimaging features and depression based on sociodemographic and functional neuroimaging features).ConclusionThese findings highlight challenges with the current disease classification system, leading us to recommend caution with the use of ICD-10 diagnostic groups as target labels in brain-based disease prediction studies.